Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC vs ASTRAZENECA PHARMA - Comparison Results

ALEMBIC     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC ASTRAZENECA PHARMA ALEMBIC/
ASTRAZENECA PHARMA
 
P/E (TTM) x 60.9 152.3 40.0% View Chart
P/BV x 5.3 42.8 12.3% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 ALEMBIC   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    ALEMBIC
Mar-18
ASTRAZENECA PHARMA
Mar-18
ALEMBIC/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs721,278 5.6%   
Low Rs34883 3.8%   
Sales per share (Unadj.) Rs4.7228.4 2.1%  
Earnings per share (Unadj.) Rs6.110.4 58.9%  
Cash flow per share (Unadj.) Rs6.216.3 38.4%  
Dividends per share (Unadj.) Rs0.200-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs40.798.8 41.2%  
Shares outstanding (eoy) m267.0325.00 1,068.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.34.7 238.2%   
Avg P/E ratio x8.7104.2 8.3%  
P/CF ratio (eoy) x8.566.4 12.8%  
Price / Book Value ratio x1.310.9 11.9%  
Dividend payout %3.30-   
Avg Mkt Cap Rs m14,13927,008 52.4%   
No. of employees `000NA1.4 0.0%   
Total wages/salary Rs m2071,535 13.5%   
Avg. sales/employee Rs ThNM4,210.9-  
Avg. wages/employee Rs ThNM1,132.2-  
Avg. net profit/employee Rs ThNM191.1-  
INCOME DATA
Net Sales Rs m1,2555,710 22.0%  
Other income Rs m370123 302.2%   
Total revenues Rs m1,6255,833 27.9%   
Gross profit Rs m111463 24.0%  
Depreciation Rs m38147 25.6%   
Interest Rs m20-   
Profit before tax Rs m442438 100.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m24179 13.4%   
Profit after tax Rs m1,630259 629.0%  
Gross profit margin %8.98.1 109.2%  
Effective tax rate %5.440.8 13.3%   
Net profit margin %129.84.5 2,861.6%  
BALANCE SHEET DATA
Current assets Rs m1,8673,209 58.2%   
Current liabilities Rs m5912,070 28.6%   
Net working cap to sales %101.620.0 509.3%  
Current ratio x3.21.6 203.7%  
Inventory Days Days9472 130.3%  
Debtors Days Days7435 210.6%  
Net fixed assets Rs m1,791790 226.6%   
Share capital Rs m53450 1,068.2%   
"Free" reserves Rs m10,3242,419 426.7%   
Net worth Rs m10,8582,469 439.7%   
Long term debt Rs m410-   
Total assets Rs m11,5914,605 251.7%  
Interest coverage x260.9NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.11.2 8.7%   
Return on assets %14.15.6 250.2%  
Return on equity %15.010.5 143.1%  
Return on capital %15.217.7 85.6%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m19300 6.5%   
Fx outflow Rs m2642,015 13.1%   
Net fx Rs m-244-1,715 14.2%   
CASH FLOW
From Operations Rs m23688 268.3%  
From Investments Rs m-224-94 239.3%  
From Financial Activity Rs m-27NA-  
Net Cashflow Rs m-15-6 259.6%  

Share Holding

Indian Promoters % 64.0 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.2 0.3 66.7%  
FIIs % 9.7 15.7 61.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 9.1 286.8%  
Shareholders   54,701 12,856 425.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC With:   BIOCON   CADILA HEALTHCARE  VENUS REMEDIES  PANACEA BIOTECH  WOCKHARDT  

Compare ALEMBIC With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Momentum Moves: The Week Gone By(Momentum Moves)

Nifty and Sensex ended the week gaining 0.60% and 0.52% respectively. Bulls started the week roaring but since Wednesday, the momentum seemed to be tiring.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Five Wishes and a Will(The Honest Truth)

Jan 4, 2021

Ajit Dayal on the investing strategy for 2021 and beyond.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC SHARE PRICE


Jan 15, 2021 (Close)

TRACK ALEMBIC

  • Track your investment in ALEMBIC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE ALEMBIC WITH

MARKET STATS